Extracellular Vesicles as Next-Generation Therapeutics: Global Pipeline, Regulatory Landscape, and Translational Challenges
Key Insights
Extracellular vesicles (EVs) from diverse sources including MSCs, immune cells, plants, and milk show therapeutic potential across tissue repair, immune modulation, oncology, and neurological disorders.
As of April 2026, no EV therapeutic product has received formal marketing approval; only 9 industry-sponsored candidates have entered registered clinical trials, with one in Phase III.
Japan's PMDA released the world's first national-level official technical guideline for EV therapeutics in August 2024, while China's CDE formally incorporated EVs into the ATMP framework in June 2025.
The field of extracellular vesicle (EV) therapeutics is advancing rapidly from preclinical promise toward clinical reality, yet as of April 2026, no EV-based therapeutic product has been formally approved for marketing anywhere in the world. A comprehensive systematic review published in the International Journal of Nanomedicine provides the most current global snapshot of the EV clinical pipeline, regulatory landscape, and the core translational challenges that must be overcome.
Among the nine industry-sponsored EV products that have entered registered clinical trials, only one has reached Phase III: Direct Biologics (search)' ExoFlo, a bone marrow MSC-derived EV product, is being evaluated for acute respiratory distress syndrome (search) (ARDS) (NCT05354141). Two candidates have advanced to Phase II: Rion/INTENT Biologics (search)' PEP-TISSEEL (search), a platelet-derived exosome product that has completed Phase II for diabetic foot ulcers (search) with FDA Fast Track designation (NCT06319287), and Aegle Therapeutics (search)' AGLE-102, a bone marrow MSC-derived EV product in Phase II for burns and epidermolysis bullosa (search) (NCT05078385, NCT04173650). The remaining six candidates are at Phase I or earlier stages, or have been terminated—most notably Codiak BioSciences (search)' engEx platform-based candidates (CDK-002/003/004) for solid tumors, which were discontinued due to bankruptcy.
Regional Development Momentum
North America leads in late-phase development, but Europe and Asia are contributing significant growth. Belgium's EXO Biologics is conducting Phase I/II trials of EXOB-001, an umbilical cord MSC-derived EV product for pediatric bronchopulmonary dysplasia (search) (NCT06279741). In South Korea, S&Ebio (search) is advancing Phase Ib of SNE-101, a Wharton's jelly MSC-derived EV product for stroke (NCT06995625), while ILIAS Biologics (search) is preparing Phase II of ILB-202, a HEK293F-engineered EV candidate (NCT05843799). In China, Shanghai Stedexo (search)'s STX11101, an engineered adipose MSC-exosome product, has received IND acceptance from the CDE for acute liver failure (CXSL2600403), and Taiwan's Shine-On Biomedical (search) is conducting Phase I trials of SOB100, an HLA-G nanobody-engineered EV product (NCT07219940).
Regulatory Frameworks Taking Shape
The global regulatory landscape for EV therapeutics is evolving rapidly, though significant divergence remains across regions. In the European Union, EV products are regulated under Directive 2001/83/EC and Regulation (EC) No 1394/2007 on advanced therapy medicinal products (ATMPs). EVs carrying functional nucleic acids that mediate therapeutic effects are classified as gene therapy medicinal products and must undergo full ATMP review. In the United States, the FDA's Center for Biologics Evaluation and Research (CBER) oversees EV therapeutics under Section 351 of the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act.
A landmark development occurred in August 2024 when Japan's Pharmaceuticals and Medical Devices Agency (PMDA) released the Quality and Safety Assessment Report for Extracellular Vesicle Therapeutic Products, representing the world's first national-level official technical guideline dedicated to EV drug development. In China, the Center for Drug Evaluation (CDE) issued a draft guidance in June 2025 formally incorporating EV therapeutics into the ATMP framework, classifying them as either novel delivery system drugs or cell derivative products based on composition and mechanism. In August 2025, the National Institutes for Food and Drug Control (NIFDC) published the first official technical review supporting the druggability of EV products.
Source-Dependent Therapeutic Applications
The review systematically characterizes EVs from multiple sources, each with distinct therapeutic preferences. Mesenchymal stem cell-derived EVs (MSC-EVs) exhibit the broadest route adaptability, with umbilical cord-derived MSC-EVs extensively investigated for type 2 diabetes mellitus and diabetic complications, while adipose-derived MSC-EVs show preclinical efficacy in osteoarthritis. Immune cell-derived EVs, particularly NK cell-derived EVs, demonstrate direct cytotoxicity against breast cancer, melanoma, and hematological malignancies through perforin, granzyme, and TRAIL-mediated mechanisms.
Plant-derived EVs (PDEVs) from ginger, grape, grapefruit, and broccoli possess exceptional gastrointestinal stability and low immunogenicity, supporting oral administration feasibility. Bovine milk-derived EVs exhibit extraordinary stability resisting gastric acid, digestive enzymes, and thermal processing, enabling oral delivery that overcomes the poor oral bioavailability limitation of most mammalian EVs.
Core Translational Challenges
Despite extensive preclinical validation, six interconnected bottlenecks persist. First, the therapeutic mechanisms and key effector components of EVs remain insufficiently defined, hindering mechanism-guided optimization. Second, no validated functional potency assays are available to reflect real in vivo therapeutic efficacy. Third, cGMP-compliant manufacturing processes remain incomplete, with significant batch-to-batch variability in particle size, cargo composition, and biological activity. Fourth, no global consensus exists on standardized critical quality attributes (CQAs). Fifth, unclear in vivo biodistribution due to deficient real-time tracing technologies hampers accurate assessment of tissue targeting and metabolic fate. Sixth, global regulatory alignment is lacking, with classification principles differing across regions.
The review authors propose six targeted developmental priorities: defining core functional components and dose-effect correlations; establishing standardized cGMP-compliant production and purification workflows; formulating globally unified CQA specifications; launching multi-center, long-term follow-up clinical trials; developing surface modification and intelligent delivery strategies; and promoting cross-border regulatory cooperation.
Administration Route Matching
The review emphasizes that administration route selection must be rationally matched with disease type, lesion location, and EV source characteristics. Intravenous injection enables systemic distribution for metabolic and neurodegenerative diseases but faces rapid clearance by the mononuclear phagocyte system. Nasal instillation allows EVs to bypass the blood-brain barrier via olfactory and trigeminal nerve pathways for CNS disorders. Oral administration is feasible for PDEVs and milk-derived EVs with inherent gastrointestinal stability. Aerosol inhalation achieves high local lung concentrations for respiratory diseases, while intra-articular and intravitreal injections enable direct local enrichment for joint and ocular disorders, respectively.
As the field matures, EVs are positioned to complement conventional small-molecule and biological therapies by offering superior targeting, biocompatibility, and multi-target therapeutic capacity, while avoiding the safety risks of living cell therapies including abnormal proliferation, ectopic differentiation, and tumorigenicity.